Heart and kidney disease screening in people hospitalized for a COPD flare-up
Checks for hidden heart and kidney disease in people admitted with a COPD flare-up.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Shatin, Hong KongSee the site
- Trial code
- Registry title
- A Prospective Study of Cardiovascular Risk of Patients Admitted for Acute Exacerbation of COPD
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 15 Jan 2026
- Expected to end
- 28 Feb 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Intervention Group
- Usual Care
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older who are in hospital because their COPD has flared up. It checks for hidden heart and kidney disease.
- Age
- 40 years or older
- Sex
- All sexes
- Disease stage
- Hospitalized for a COPD exacerbation, with COPD confirmed by an FEV1/FVC ratio below 0.70
- Biomarker or test result
- FEV1/FVC ratio below 0.70
Main reasons for not taking part
- Pregnant people
- People who cannot give informed consent
- People with cancer on active chemotherapy or palliative care
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥40 years
- Patients hospitalized due to COPD exacerbation
- Patients diagnosed with COPD, a confirmed COPD diagnosis with a specific FEV1/FVC ratio (<0.70)
- Able to provide informed consent
Who cannot take part
- Cancer patient who are on active chemotherapy or on palliative care
- Pregnant subjects
- Inability to give informed consent
Where in Hong Kong
- Prince of Wales HospitalShatin, Hong KongContact: Fanny WS Ko, MDTaking people
About the trial
What the trial wants to find out
This is a prospective study to assess the burden of existing or hidden cardiovascular (CV) and renal disease in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a Hong Kong public hospital setting. By implementing a chronic obstructive pulmonary disease (COPD) discharge care bundle with integrated CV/renal screening, the study aims to quantify undiscovered disease prevalence, evaluate risk factors for future exacerbations, and compare re-admission rates against historical controls, ultimately informing integrated cardiopulmonary management strategies.
The 2 groups in the trial
- Implementation of the COPD discharge care bundleTreatment being tested
Prospective recruitment with implementation of the COPD discharge care bundle
Treatment: Intervention Group
- Historic controlsOther group
Historical records of prior acute exacerbation of COPD episodes and management under standard care from the database
Treatment: Usual Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective Study of Cardiovascular Risk of Patients Admitted for Acute Exacerbation of COPD
- Plain-language title
- Heart and kidney disease screening in people hospitalized for a COPD flare-upGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 October 2026